Clinical Trial Update: A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating darbepoetin alfa for treating anemia in patients with low-risk myelodysplastic syndromes, sponsored by Amgen, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Amgen | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED